Related Experiment Video
Updated: Oct 18, 2025

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Valve-in-Valve Transcatheter Aortic Valve Replacement, with Present-Day Innovations and Up-to-Date Techniques
Salem A Salem1, Jason R Foerst1
1Structural and Interventional Cardiology, Virginia Tech Carilion School of Medicine, Carilion Clinic, 1906 Belleview Avenue SE, Roanoke, VA 24014, USA.
Abstract:
Approximately 51,000 to 65,000 surgical aortic valve replacement (SAVR) cases are performed in the United States anually. Bioprosthetic degeneration commonly occurs within 10 to 15 years, and nearly 800 redo SAVR cases occur each year. Valve-in-valve transcatheter aortic valve replacement (ViV TAVR) has emerged as a safe and effective alternative, as the Food and Drug Administration approved ViV TAVR with self-expanding transcatheter heart valve in 2015 and balloon-expandable valve in 2017 for failed surgical valves cases at high risk of reoperation. We review ViV TAVR, with specific attention to procedural planning, technical challenges, associated complications, and long-term follow-up.
More Related Videos
Related Concept Videos
Mitral Stenosis III: Medical Management
Aortic Regurgitation III: Medical Management
Cardiac Catheterization I: Pre-Procedure Overview

